Morgan Hicks, PA
Medical · Dillon, SCNPI 1679035158
Payments from drug & device makers
Across 174 payments — averaging $15.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$692
- AbbVie$179
- Pfizer$171
- Novartis$168
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$157
- GSK$132
- plus $1K from 29 others
What the payments were for
- Food & beverage$2,779100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 42 | $692 |
| AbbVie | 10 | $179 |
| Pfizer | 12 | $171 |
| Novartis | 11 | $168 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $157 |
| GSK | 8 | $132 |
| Amgen | 8 | $119 |
| Abbott | 6 | $111 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $101 |
| Exact Sciences | 6 | $100 |
| Sumitomo Pharma America, Inc. | 4 | $74 |
| AstraZeneca | 5 | $72 |
| Boehringer Ingelheim | 4 | $61 |
| Lilly USA, LLC | 4 | $59 |
| Dexcom, Inc. | 4 | $57 |
| Corcept Therapeutics | 3 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $47 |
| Amarin Pharma, Inc. | 3 | $43 |
| Sanofi-aventis U.S. LLC | 3 | $39 |
| Daiichi Sankyo Inc. | 2 | $38 |
| Bayer | 2 | $29 |
| Johnson & Johnson | 2 | $29 |
| Eisai Inc. | 2 | $27 |
| Mylan Specialty L.p. | 2 | $26 |
| VBI Vaccine (delaware) Inc. | 2 | $24 |
| Dynavax Technologies Corporation | 2 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Supernus Pharmaceuticals, Inc. | 1 | $23 |
| Cvrx, Inc. | 1 | $18 |
| Hologic Sales And Service, LLC | 1 | $18 |
| Nevro Corp. | 1 | $16 |
| Almatica Pharma LLC | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
| Edwards Lifesciences | 1 | $13 |
| Forte Bio-pharma LLC | 1 | $7 |
How this compares
$2,779 in reported general payments places this provider in the 70th percentile of 384 medical providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 117 | $143,041 |
| OzempicSemaglutide | 93 | $97,105 |
| JardianceEmpagliflozin | 75 | $78,778 |
| EliquisApixaban | 89 | $69,341 |
| LinzessLinaclotide | 68 | $58,900 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 56 | $40,019 |
| TrulicityDulaglutide | 34 | $32,011 |
| RybelsusSemaglutide | 22 | $25,157 |
| XareltoRivaroxaban | 31 | $25,073 |
| UbrelvyUbrogepant | 15 | $22,943 |
| JanuviaSitagliptin Phosphate | 27 | $22,778 |
| QuliptaAtogepant | 13 | $20,246 |
| FarxigaDapagliflozin Propanediol | 17 | $16,602 |
| TradjentaLinagliptin | 16 | $11,977 |
| MyrbetriqMirabegron | 20 | $10,292 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $59 | $175,052151 claims |
| Novo NordiskOzempic, Rybelsus | $692 | $122,262115 claims |
| AbbVieLinzess, Ubrelvy, Qulipta, Synthroid | $179 | $103,771135 claims |
| Boehringer IngelheimJardiance, Tradjenta | $61 | $90,75491 claims |
| PfizerEliquis | $171 | $69,34189 claims |
| GSKTrelegy Ellipta | $132 | $40,01956 claims |
| Johnson & JohnsonXarelto | $29 | $25,07331 claims |
| AstraZenecaFarxiga, Symbicort | $72 | $21,88732 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $74 | $9,47916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 384 medical providers in South Carolina.
Other medical in Dillon
- Christopher ThompsonSpartanburg$78K
- Laura BuchGreenville$73K
- Suzanne SmithWest Columbia$39K
- Stavros ChrysostomidesColumbia$39K
- Ethan CaseySpartanburg$24K
- Jessica HallColumbia$22K
- Mary MacdonaldCharleston$20K
- Cameron PappasGreenville$18K
- Leslie RumbautGrenville$18K
- Claire DukeGreenville$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.